X4 Pharmaceuticals Inc
XFOR
Company Profile
Business description
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company’s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Contact
61 North Beacon Street
4th Floor
BostonMA02134
USAT: +1 857 529-8300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
143
Stocks News & Analysis
stocks
Chart of the Week: We see opportunity in Mineral Resources despite debt concerns
Shares trade at a discount despite attractive longer-term outlook.
stocks
The ultimate investing hack: dividend growth stocks
Finding companies built for lasting dividend growth.
stocks
Is the data centre party over for Goodman?
Global spending spree on data centres could mean a declining return on invested capital.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,903.40 | 3.40 | -0.04% |
| CAC 40 | 8,122.03 | 34.61 | 0.43% |
| DAX 40 | 23,882.03 | 188.32 | 0.79% |
| Dow JONES (US) | 47,850.94 | 31.96 | -0.07% |
| FTSE 100 | 9,710.87 | 18.80 | 0.19% |
| HKSE | 25,935.90 | 175.17 | 0.68% |
| NASDAQ | 23,505.14 | 51.04 | 0.22% |
| Nikkei 225 | 51,028.42 | 1,163.74 | 2.33% |
| NZX 50 Index | 13,475.41 | 40.21 | -0.30% |
| S&P 500 | 6,857.12 | 7.40 | 0.11% |
| S&P/ASX 200 | 8,610.60 | 3.50 | -0.04% |
| SSE Composite Index | 3,875.79 | 2.21 | -0.06% |